A network meta-analysis of the dose–response effects of lurasidone on acute schizophrenia

Abstract We compared the efficacy, safety, and acceptability of lurasidone at different doses to establish the dose–response relationships of lurasidone therapeutic and adverse effects in acute schizophrenia. Included trials were 4- to 16-week, fixed-dose, randomized controlled trials of lurasidone...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Manit Srisurapanont, Sirijit Suttajit, Surinporn Likhitsathian, Benchalak Maneeton, Narong Maneeton
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/8180d6af46654656b599de43a66921d3
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8180d6af46654656b599de43a66921d3
record_format	dspace
spelling	oai:doaj.org-article:8180d6af46654656b599de43a66921d32021-12-02T13:19:29ZA network meta-analysis of the dose–response effects of lurasidone on acute schizophrenia10.1038/s41598-021-84836-z2045-2322https://doaj.org/article/8180d6af46654656b599de43a66921d32021-03-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-84836-zhttps://doaj.org/toc/2045-2322Abstract We compared the efficacy, safety, and acceptability of lurasidone at different doses to establish the dose–response relationships of lurasidone therapeutic and adverse effects in acute schizophrenia. Included trials were 4- to 16-week, fixed-dose, randomized controlled trials of lurasidone in adults with acute schizophrenia. Different doses of lurasidone, other antipsychotics, and placebo were considered as independent treatments. Apart from all-cause dropout rates, four therapeutic and four adverse outcomes were included in the frequentist network meta-analysis (NMA). Lurasidone 160, 120, 80, 40, and 20 mg/day were studied in ten trials of 3,366 adults with schizophrenia exacerbation. Lurasidone 160 mg/day reduced Positive and Negative Syndrome Scale (PANSS) total scores significantly more than lurasidone 120, 80, 40, and 20 mg/day (mean differences = − 7.63, − 7.04, − 8.83, and − 12.25, respectively). All-cause dropout rates were significantly lower in participants receiving lurasidone 160 mg/day and 80 mg/day compared with those taking placebo. The half-maximal effective doses of lurasidone for PANSS total, PANSS positive, and MADRS score reductions were higher than 80 mg/day. The confidence of all NMA estimates was low or very low. Lurasidone 160 mg/day is currently the most efficacious and acceptable dose for acute schizophrenia. Its maximal effective doses may be higher than 160 mg/day.Manit SrisurapanontSirijit SuttajitSurinporn LikhitsathianBenchalak ManeetonNarong ManeetonNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-13 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Manit Srisurapanont Sirijit Suttajit Surinporn Likhitsathian Benchalak Maneeton Narong Maneeton A network meta-analysis of the dose–response effects of lurasidone on acute schizophrenia
description	Abstract We compared the efficacy, safety, and acceptability of lurasidone at different doses to establish the dose–response relationships of lurasidone therapeutic and adverse effects in acute schizophrenia. Included trials were 4- to 16-week, fixed-dose, randomized controlled trials of lurasidone in adults with acute schizophrenia. Different doses of lurasidone, other antipsychotics, and placebo were considered as independent treatments. Apart from all-cause dropout rates, four therapeutic and four adverse outcomes were included in the frequentist network meta-analysis (NMA). Lurasidone 160, 120, 80, 40, and 20 mg/day were studied in ten trials of 3,366 adults with schizophrenia exacerbation. Lurasidone 160 mg/day reduced Positive and Negative Syndrome Scale (PANSS) total scores significantly more than lurasidone 120, 80, 40, and 20 mg/day (mean differences = − 7.63, − 7.04, − 8.83, and − 12.25, respectively). All-cause dropout rates were significantly lower in participants receiving lurasidone 160 mg/day and 80 mg/day compared with those taking placebo. The half-maximal effective doses of lurasidone for PANSS total, PANSS positive, and MADRS score reductions were higher than 80 mg/day. The confidence of all NMA estimates was low or very low. Lurasidone 160 mg/day is currently the most efficacious and acceptable dose for acute schizophrenia. Its maximal effective doses may be higher than 160 mg/day.
format	article
author	Manit Srisurapanont Sirijit Suttajit Surinporn Likhitsathian Benchalak Maneeton Narong Maneeton
author_facet	Manit Srisurapanont Sirijit Suttajit Surinporn Likhitsathian Benchalak Maneeton Narong Maneeton
author_sort	Manit Srisurapanont
title	A network meta-analysis of the dose–response effects of lurasidone on acute schizophrenia
title_short	A network meta-analysis of the dose–response effects of lurasidone on acute schizophrenia
title_full	A network meta-analysis of the dose–response effects of lurasidone on acute schizophrenia
title_fullStr	A network meta-analysis of the dose–response effects of lurasidone on acute schizophrenia
title_full_unstemmed	A network meta-analysis of the dose–response effects of lurasidone on acute schizophrenia
title_sort	network meta-analysis of the dose–response effects of lurasidone on acute schizophrenia
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/8180d6af46654656b599de43a66921d3
work_keys_str_mv	AT manitsrisurapanont anetworkmetaanalysisofthedoseresponseeffectsoflurasidoneonacuteschizophrenia AT sirijitsuttajit anetworkmetaanalysisofthedoseresponseeffectsoflurasidoneonacuteschizophrenia AT surinpornlikhitsathian anetworkmetaanalysisofthedoseresponseeffectsoflurasidoneonacuteschizophrenia AT benchalakmaneeton anetworkmetaanalysisofthedoseresponseeffectsoflurasidoneonacuteschizophrenia AT narongmaneeton anetworkmetaanalysisofthedoseresponseeffectsoflurasidoneonacuteschizophrenia AT manitsrisurapanont networkmetaanalysisofthedoseresponseeffectsoflurasidoneonacuteschizophrenia AT sirijitsuttajit networkmetaanalysisofthedoseresponseeffectsoflurasidoneonacuteschizophrenia AT surinpornlikhitsathian networkmetaanalysisofthedoseresponseeffectsoflurasidoneonacuteschizophrenia AT benchalakmaneeton networkmetaanalysisofthedoseresponseeffectsoflurasidoneonacuteschizophrenia AT narongmaneeton networkmetaanalysisofthedoseresponseeffectsoflurasidoneonacuteschizophrenia
_version_	1718393283609100288

A network meta-analysis of the dose–response effects of lurasidone on acute schizophrenia

Ejemplares similares